4581 — Taisho Pharmaceutical Holdings Co Income Statement
0.000.00%
- ¥704bn
- ¥463bn
- ¥301bn
- 72
- 35
- 96
- 82
Annual income statement for Taisho Pharmaceutical Holdings Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 261,551 | 288,527 | 281,980 | 268,203 | 301,381 |
Cost of Revenue | |||||
Gross Profit | 170,345 | 180,141 | 175,930 | 163,832 | 177,850 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 249,608 | 261,888 | 264,419 | 258,412 | 279,930 |
Operating Profit | 11,943 | 26,639 | 17,561 | 9,791 | 21,451 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 64,484 | 29,775 | 22,976 | 21,398 | 29,498 |
Provision for Income Taxes | |||||
Net Income After Taxes | 49,826 | 21,530 | 15,194 | 14,950 | 21,302 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 48,595 | 20,174 | 13,316 | 13,122 | 18,997 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 48,592 | 20,170 | 13,315 | 13,122 | 18,997 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 395 | 271 | 283 | 265 | 340 |
Dividends per Share | |||||
Special Dividends per Share |